Code Biotherapeutics

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Code Biotherapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care sector. The company focuses on Biotechnology and has secured $2.0B in funding across 24 round(s). With a team of 11-50 employees, Code Biotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Code Biotherapeutics, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.